• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by VistaGen Therapeutics Inc. (Amendment)

    2/14/24 8:56:03 AM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VTGN alert in real time by email
    SC 13G/A 1 p24-0640sc13ga.htm VISTAGEN THERAPEUTICS, INC.
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
     

    Vistagen Therapeutics, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)
     

    92840H400

    (CUSIP Number)
     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    ý Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 92840H40013G/APage 2 of 7 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Point72 Asset Management, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    822,334 shares of Common Stock issuable upon exercise of warrants

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    822,334 shares of Common Stock issuable upon exercise of warrants

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    822,334 shares of Common Stock issuable upon exercise of warrants

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.0%

    12

    TYPE OF REPORTING PERSON

    PN

             

     

     

    CUSIP No. 92840H40013G/APage 3 of 7 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Point72 Capital Advisors, Inc.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    822,334 shares of Common Stock issuable upon exercise of warrants

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    822,334 shares of Common Stock issuable upon exercise of warrants

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    822,334 shares of Common Stock issuable upon exercise of warrants

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.0%

    12

    TYPE OF REPORTING PERSON

    CO

             

     

     

    CUSIP No. 92840H40013G/APage 4 of 7 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Steven A. Cohen

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    822,334 shares of Common Stock issuable upon exercise of warrants

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    822,334 shares of Common Stock issuable upon exercise of warrants

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    822,334 shares of Common Stock issuable upon exercise of warrants

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.0%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

    CUSIP No. 92840H40013G/APage 5 of 7 Pages

      

    Item 1(a). Name of Issuer:
      Vistagen Therapeutics, Inc. (the “Issuer”).
       
    Item 1(b). Address of Issuer's Principal Executive Offices:
      343 Allerton Avenue, South San Francisco, CA 94080.
       
    Item 2(a). Name of Person Filing:
      This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset Management”) with respect to shares of common stock, par value $0.001 per share (“Common Stock”), of the Issuer held by (and underlying warrants held by) an investment fund it manages; (ii) Point72 Capital Advisors, Inc. (“Point72 Capital Advisors Inc.”) with respect to the Shares of Common Stock held by (and underlying warrants held by) an investment fund managed by Point72 Asset Management; and (iii) Steven A. Cohen (“Mr. Cohen”) with respect to the shares of Common Stock beneficially owned by Point72 Asset Management and Point72 Capital Advisors Inc.
       
    Item 2(b). Address of Principal Business Office:
      The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902.
       
    Item 2(c). Place of Organization:
      Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation.  Mr. Cohen is a United States citizen.
       
    Item 2(d). Title of Class of Securities:
      Common Stock, par value $0.001 per share.
       
    Item 2(e). CUSIP Number:
      92840H400
       
    Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a:
      Not applicable.
       
    Item 4. Ownership:
      The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.  Such information is as of the close of business on December 31, 2023.
       
      Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no shares of Common Stock. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by an investment fund it manages. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management.  Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors Inc.   The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock reported herein.

     

    CUSIP No. 92840H40013G/APage 6 of 7 Pages

     

     

       
    Item 5. Ownership of Five Percent or Less of a Class:
      If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following x.
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person:
      See item 2(a).
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:
      Not applicable.
       
    Item 8. Identification and Classification of Members of the Group:
      Not applicable.
       
    Item 9. Notice of Dissolution of Group:
      Not applicable.
       
    Item 10. Certification:
      By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
       

     

     

    CUSIP No. 92840H40013G/APage 7 of 7 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date:  February 14, 2024  
      POINT72 ASSET MANAGEMENT, L.P.
       
      By:  /s/ Jason M. Colombo
      Name:  Jason M. Colombo
     

    Title: Authorized Person

     

     

      POINT72 CAPITAL ADVISORS, INC.
       
      By:  /s/ Jason M. Colombo
      Name:  Jason M. Colombo
      Title:    Authorized Person

     

       
      STEVEN A. COHEN
       
      By:  /s/ Jason M. Colombo
      Name:  Jason M. Colombo
      Title:    Authorized Person
       

     

    Get the next $VTGN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $VTGN

    DatePrice TargetRatingAnalyst
    12/7/2023$15.00Hold → Buy
    Jefferies
    8/7/2023$30.00Hold → Buy
    Maxim Group
    7/22/2022Outperform → Neutral
    Robert W. Baird
    7/22/2022Buy → Hold
    Jefferies
    7/22/2022Outperform → Mkt Perform
    William Blair
    More analyst ratings

    $VTGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vistagen Appoints Elissa Cote as Chief Corporate Development Officer

      Accomplished biopharma executive brings nearly 30 years of experience in business development, enterprise strategy, and global partnerships to her role Ms. Cote to help drive the strategic positioning of Vistagen's clinical-stage pipeline, which includes five novel intranasal pherine candidates targeting six highly prevalent and underserved disorders Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Elissa Cote as Chief Corporate Development Officer. In this role, Ms. Cote will lead t

      6/25/25 8:30:00 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

      Topline results of PALISADE-3 Phase 3 Trial of fasedienol for acute treatment of social anxiety disorder expected in the fourth quarter of this year PALISADE-4 Phase 3 Trial topline results expected in the first half of 2026 Company showcases promising clinical-stage pipeline of five novel intranasal pherine candidates targeting six highly prevalent and underserved disorders Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year ended March 31, 2025, and provided a corp

      6/17/25 4:30:00 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025

      Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Tuesday, June 17, 2025, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2025 ended March 31, 2025, and provide a corporate update. The conference call is being webcast live, and a link can be found under "Events" in the Investors section of the Company's website. Participants may register to join the live call by following the link here to receive the dial-in numbers and

      6/12/25 8:30:00 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • VistaGen upgraded by Jefferies with a new price target

      Jefferies upgraded VistaGen from Hold to Buy and set a new price target of $15.00

      12/7/23 6:31:15 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VistaGen upgraded by Maxim Group with a new price target

      Maxim Group upgraded VistaGen from Hold to Buy and set a new price target of $30.00

      8/7/23 2:16:37 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VistaGen downgraded by Robert W. Baird

      Robert W. Baird downgraded VistaGen from Outperform to Neutral

      7/22/22 12:22:03 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Prince Joshua S. was granted 4,882 shares, increasing direct ownership by 82% to 10,863 units (SEC Form 4)

      4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)

      7/1/25 5:51:38 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Legal Officer Adler Reid G. was granted 7,541 shares, increasing direct ownership by 46% to 24,050 units (SEC Form 4)

      4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)

      7/1/25 5:50:42 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF FINANCIAL OFFICER Anderson Cynthia Lynn was granted 6,617 shares, increasing direct ownership by 107% to 12,801 units (SEC Form 4)

      4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)

      7/1/25 5:49:44 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTGN
    SEC Filings

    See more
    • Vistagen Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)

      6/25/25 4:59:22 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vistagen Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

      8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)

      6/17/25 4:44:53 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Vistagen Therapeutics Inc.

      424B5 - Vistagen Therapeutics, Inc. (0001411685) (Filer)

      6/17/25 4:43:16 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTGN
    Leadership Updates

    Live Leadership Updates

    See more
    • Vistagen Appoints Elissa Cote as Chief Corporate Development Officer

      Accomplished biopharma executive brings nearly 30 years of experience in business development, enterprise strategy, and global partnerships to her role Ms. Cote to help drive the strategic positioning of Vistagen's clinical-stage pipeline, which includes five novel intranasal pherine candidates targeting six highly prevalent and underserved disorders Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Elissa Cote as Chief Corporate Development Officer. In this role, Ms. Cote will lead t

      6/25/25 8:30:00 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day

      Vistagen CEO Shawn Singh; The Goldie Hawn Foundation Founder Goldie Hawn; and MindUP students to ring the Nasdaq Closing Bell on October 10, 2024 Vistagen and The Goldie Hawn Foundation join forces to raise awareness around the roles of mindfulness and pioneering neuroscience in mental health Vistagen (NASDAQ:VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development of groundbreaking therapies for psychiatric disorders based on nose-to-brain neurocircuitry, and The Goldie Hawn Foundation's MindUP, a neuroscience-based preventative mental health program for youth, along with children from New York City schools utilizing MindUP, will join toget

      10/9/24 8:30:00 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vistagen Appoints Cindy Anderson as Chief Financial Officer

      Anderson succeeds Jerrold Dotson who is retiring after a distinguished decade-long career with Vistagen Vistagen (NASDAQ:VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced the appointment of Cindy Anderson as Chief Financial Officer (CFO), effective August 21, 2023. Ms. Anderson will succeed Jerrold Dotson, whose planned retirement was announced in July of this year. "We are delighted to welcome Ms. Anderson, an experienced and highly accomplished finance professional, to our team," said Shawn Singh, Chief Executive Officer of V

      8/22/23 8:30:00 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Vistagen Therapeutics Inc.

      SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)

      11/14/24 5:05:41 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Vistagen Therapeutics Inc.

      SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)

      11/14/24 4:19:46 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by VistaGen Therapeutics Inc. (Amendment)

      SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)

      2/14/24 6:18:34 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTGN
    Financials

    Live finance-specific insights

    See more
    • Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

      Topline results of PALISADE-3 Phase 3 Trial of fasedienol for acute treatment of social anxiety disorder expected in the fourth quarter of this year PALISADE-4 Phase 3 Trial topline results expected in the first half of 2026 Company showcases promising clinical-stage pipeline of five novel intranasal pherine candidates targeting six highly prevalent and underserved disorders Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year ended March 31, 2025, and provided a corp

      6/17/25 4:30:00 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025

      Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Tuesday, June 17, 2025, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2025 ended March 31, 2025, and provide a corporate update. The conference call is being webcast live, and a link can be found under "Events" in the Investors section of the Company's website. Participants may register to join the live call by following the link here to receive the dial-in numbers and

      6/12/25 8:30:00 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update

      Fasedienol U.S. registration-directed PALISADE Phase 3 Program for acute treatment of social anxiety disorder progressing with ongoing PALISADE-3, PALISADE-4 and Repeat Dose trials Vistagen highlights clinical-stage pipeline with five novel pherine product candidates with positive efficacy signals and potential to transform standards of care for multiple high prevalence indications Vistagen (NASDAQ:VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2025 third quarter ended December 31, 202

      2/13/25 4:30:00 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care